Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP

摘要

OBJECTIVE: This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant human thrombopoietin in treating immune thrombocytopenia (ITP). PATIENTS AND METHODS: Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 μg/kg/d ih recombinant human thrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment. RESULTS: Among the 14 patients, seven complete responses, six responses, and one no response were obtained, with an overall response of 93%. CONCLUSIONS: Low-dose rituximab in combination with rhTPO is effective in treating ITP.